Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis.

Kokkali, Stefania; Ternant, David; Kemmel, Véronique; Levêque, Dominique; Wendling, Fréderique; Barthelemy, Philippe; Kurtz, Jean-Emmanuel

Kokkali, Stefania; Ternant, David; Kemmel, Véronique; Levêque, Dominique; Wendling, Fréderique; Barthelemy, Philippe; Kurtz, Jean-Emmanuel.

Afiliación

Kokkali S; Department of Medical Oncology, Strasbourg University Hospital, Strasbourg, France.
Ternant D; First Medical Oncology Department, Saint-Savvas Anticancer Hospital, Athens, Greece.
Kemmel V; Department of Medical Pharmacology, CHRU de Tours, Tours University Hospital, Tours, France.
Levêque D; Biochemistry and Molecular Biology Department, Strasbourg University Hospital, Strasbourg, France.
Wendling F; Pharmacy Department, Strasbourg University Hospital, Strasbourg, France.
Barthelemy P; Department of Medical Oncology, Strasbourg University Hospital, Strasbourg, France.
Kurtz JE; Department of Medical Oncology, Strasbourg University Hospital, Strasbourg, France.

Br J Clin Pharmacol ; 87(8): 3372-3374, 2021 08.

Article en En | MEDLINE | ID: mdl-33464605

Asunto(s)

Diálisis Peritoneal; Receptor ErbB-2; Administración Intravenosa; Humanos; Diálisis Peritoneal/efectos adversos; Trastuzumab/efectos adversos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diálisis Peritoneal / Receptor ErbB-2 Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google